Sabal Trust’s Amedisys AMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $556K | Hold |
6,000
| – | – | 0.03% | 178 |
|
|
2024
Q4 | $545K | Hold |
6,000
| – | – | 0.03% | 178 |
|
|
2024
Q3 | $579K | Hold |
6,000
| – | – | 0.03% | 161 |
|
|
2024
Q2 | $551K | Hold |
6,000
| – | – | 0.03% | 154 |
|
|
2024
Q1 | $553K | Hold |
6,000
| – | – | 0.03% | 149 |
|
|
2023
Q4 | $570K | Hold |
6,000
| – | – | 0.04% | 148 |
|
|
2023
Q3 | $560K | Hold |
6,000
| – | – | 0.04% | 133 |
|
|
2023
Q2 | $549K | Hold |
6,000
| – | – | 0.03% | 138 |
|
|
2023
Q1 | $441K | Hold |
6,000
| – | – | 0.03% | 98 |
|
|
2022
Q4 | $501K | Hold |
6,000
| – | – | 0.03% | 97 |
|
|
2022
Q3 | $581K | Hold |
6,000
| – | – | 0.04% | 92 |
|
|
2022
Q2 | $631K | Buy |
+6,000
| New | +$767K | 0.05% | 88 |
|
|
2022
Q1 | – | Sell |
-6,000
| Closed | -$971K | – | 145 |
|
|
2021
Q4 | $971K | Sell |
6,000
-38
| -0.6% | -$6.11K | 0.06% | 80 |
|
|
2021
Q3 | $900K | Hold |
6,038
| – | – | 0.06% | 81 |
|
|
2021
Q2 | $1.48M | Hold |
6,038
| – | – | 0.11% | 62 |
|
|
2021
Q1 | $1.6M | Hold |
6,038
| – | – | 0.12% | 65 |
|
|
2020
Q4 | $1.77M | Buy |
6,038
+38
| +0.6% | +$9.74K | 0.14% | 62 |
|
|
2020
Q3 | $1.42M | Hold |
6,000
| – | – | 0.12% | 64 |
|
|
2020
Q2 | $1.19M | Hold |
6,000
| – | – | 0.11% | 65 |
|
|
2020
Q1 | $1.1M | Hold |
6,000
| – | – | 0.12% | 58 |
|
|
2019
Q4 | $1M | Hold |
6,000
| – | – | 0.08% | 73 |
|
|
2019
Q3 | $786K | Hold |
6,000
| – | – | 0.06% | 80 |
|
|
2019
Q2 | $728K | Hold |
6,000
| – | – | 0.06% | 78 |
|
|
2019
Q1 | $740K | Hold |
6,000
| – | – | 0.07% | 80 |
|
|
2018
Q4 | $703K | Hold |
6,000
| – | – | 0.07% | 81 |
|
|
2018
Q3 | $750K | Hold |
6,000
| – | – | 0.07% | 83 |
|
|
2018
Q2 | $513K | Hold |
6,000
| – | – | 0.05% | 96 |
|
|
2018
Q1 | $362K | Hold |
6,000
| – | – | 0.03% | 117 |
|
|
2017
Q4 | $316K | Hold |
6,000
| – | – | 0.03% | 106 |
|
|
2017
Q3 | $336K | Hold |
6,000
| – | – | 0.03% | 106 |
|
|
2017
Q2 | $377K | Hold |
6,000
| – | – | 0.04% | 97 |
|
|
2017
Q1 | $307K | Hold |
6,000
| – | – | 0.03% | 107 |
|
|
2016
Q4 | $256K | Hold |
6,000
| – | – | 0.03% | 106 |
|
|
2016
Q3 | $285K | Hold |
6,000
| – | – | 0.03% | 108 |
|
|
2016
Q2 | $303K | Hold |
6,000
| – | – | 0.03% | 97 |
|
|
2016
Q1 | $290K | Hold |
6,000
| – | – | 0.03% | 95 |
|
|
2015
Q4 | $236K | Hold |
6,000
| – | – | 0.03% | 111 |
|
|
2015
Q3 | $228K | Hold |
6,000
| – | – | 0.03% | 99 |
|
|
2015
Q2 | $238K | Buy |
+6,000
| New | +$187K | 0.03% | 100 |
|
Other funds holding AMED
PCM
DKCM
AAM
TAL
UOC
Sabal Trust's AMED Position: Q1 2025 in Review
Sabal Trust held its Amedisys (AMED) position steady in Q1 2025 at 6,000 shares worth $556K. The position accounts for 0.03% of the portfolio, ranked #178.
Sabal Trust first reported a position in AMED in Q2 2015 and has held it in 39 quarters since. The position peaked at $1.77M in Q4 2020. 305 funds tracked by Wall St. Rank hold AMED as of Q1 2025.
- Sabal Trust held 6,000 shares of Amedisys worth $556K as of Q1 2025.
- Sabal Trust left its Amedisys share count unchanged in Q1 2025.
- Amedisys made up 0.03% of Sabal Trust's portfolio in Q1 2025, its #178 holding.
- Sabal Trust first reported a position in Amedisys in Q2 2015 and has held it in 39 quarters since.
- Sabal Trust's Amedisys position peaked at $1.77M in Q4 2020.
- 305 funds tracked by Wall St. Rank held Amedisys as of Q1 2025.
Based on Sabal Trust's 13F filing for Q1 2025, filed 23 Apr 2025.